Sponsors (10)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Creates a set of federal actions to accelerate research, improve clinical trial access, and increase public awareness about brain tumors. It requires public reporting of NIH-funded brain tumor biospecimen collections, establishes NIH-supported research networks and awards for glioblastoma therapeutics and brain tumor cellular immunotherapy, funds pilot programs for survivorship care, and directs HHS to run a national awareness campaign and the FDA to issue guidance to reduce exclusion of brain tumor patients from other clinical trials. Provides multi-year authorizations for research and education (including $50M/yr for a glioblastoma network, $10M/yr for cellular immunotherapy awards, $10M/yr for awareness projects, and $5M/yr for survivorship pilot grants), sets deadlines for biospecimen reporting, and gives NIH authority to enforce compliance (including withholding funds for repeated violations).
The bill directs significant, targeted federal investment and coordination to accelerate brain‑tumor research, clinical trials, and survivor care—improving access and equity for many patients—but raises budgetary costs, administrative burdens, and patient‑safety and privacy tradeoffs that will need careful management.
Patients with brain tumors, researchers, and treatment centers will get substantially more federal support and coordination to speed development of new diagnostics and therapies (targeted research funding, specimen access, and incentives for multi‑institution collaboration).
People with brain tumors (including children) will have greater opportunities to enroll in clinical trials and access novel treatments sooner through funded early‑phase studies, outreach, and expanded trial inclusion rules.
Communities at higher cancer risk and underserved populations will receive culturally and linguistically tailored outreach and demonstration grants to boost awareness and equitable trial participation.
Taxpayers and the federal budget will face new spending commitments (multiple authorized programs totaling tens of millions per year through FY2030), creating budgetary trade‑offs and potential crowding out of other priorities.
Faster approvals, more early‑phase cellular immunotherapy trials, and broader trial inclusion increase the risk of serious adverse events for fragile patients if safety oversight or evidence standards are not maintained.
Concentrating funding and attention on glioblastoma/brain‑tumor research could divert limited NIH and research resources away from other cancers or public‑health priorities.
Introduced April 8, 2025 by Richard Blumenthal · Last progress April 8, 2025